Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice

Kishk, Eman Ahmed; Ali, Mohammed

doi:10.1007/s00404-012-2658-y

Cited by 25 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rodents represent the most studied model in reproductive biology. Several in vivo experimental studies have been conducted in both female mice (Table 1) [9,19,[43][44][45][46][47][48][49][50][51][52] and rats (Table 2) [38,39,41,[53][54][55][56][57][58][59][60][61][62] treated with chemotherapy.…”

Section: Experimental Preclinical Data In Female Mice and Ratsmentioning

confidence: 99%

“…In mice, the majority of the studies showed a positive effect for GnRHa treatment in preventing busulfan-, cisplatin-, docetaxel-, and cyclophosphamide-induced depletion of primordial follicles [44][45][46][47][48][49]51] with a study suggesting that the beneficial protective gonadal effect may depend on the dose of administered chemotherapy [43]. A recent study in mice showed that co-administration of GnRHa during chemotherapy improved oocyte quality and early embryo development after exposure to cyclophosphamide [46].…”

Section: Experimental Preclinical Data In Female Mice and Ratsmentioning

confidence: 99%

See 1 more Smart Citation

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application

Lambertini

Horicks

Mastro

et al. 2019

Cancer Treatment Reviews

View full text Add to dashboard Cite

Survivorship issues are an area of crucial importance to be addressed as early as possible by all health care providers dealing with cancer patients. In women diagnosed during their reproductive years, the possible occurrence of chemotherapy-induced premature ovarian insufficiency (POI) is of particular concern being associated with important menopause-related symptoms, psychosocial issues as well as infertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been studied to reduce the gonadotoxic impact of chemotherapy thus diminishing the chance of developing POI. Despite more than 30 years of research in both preclinical and clinical settings, the performance of this strategy has remained highly debated until recently. In particular, the potential mechanisms of action for the protective effects of GnRHa during chemotherapy are still not clearly identified. Nevertheless, important novel research efforts in the field have better elucidated the role of this option that is now endorsed for clinical use by several guidelines. This manuscript aims at providing an extensive overview of the literature on the use of temporary ovarian suppression with GnRHa during chemotherapy in cancer patients by addressing its biological rationale, the available preclinical and clinical evidence as well as the still existing grey zones in this field that future research efforts should address.

show abstract

Section: Experimental Preclinical Data In Female Mice and Ratsmentioning

confidence: 99%

Section: Experimental Preclinical Data In Female Mice and Ratsmentioning

confidence: 99%

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application

Lambertini

Horicks

Mastro

et al. 2019

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…1 However, young female patients are still being poorly counseled with regard to the negative impact of treatment on their fertility for fertility preservation. It has been estimated that 10% of women become infertile early in life due to a premature critical loss of oocytes which caused an accelerated rate of loss of the oocyte pool through detrimental exposures (smoking, occupational exposures or chemotherapy).…”

Section: Introductionmentioning

confidence: 99%

The effects ofN-acetyl-l-cysteine on the female reproductive performance and nephrotoxicity in rats

Helal

2016

Renal Failure

View full text Add to dashboard Cite

This study was designed to investigate whether the treatment with the N-acetyl-L-cysteine prior to the administration of chemotherapy drug would prevent from nephrotoxicity and the loss of reproductive performance induced from chemotherapy treatment. Female rats were divided into five equal groups of six each: 1/control group; 2/rats i.p administered saline solution; 3/rats i.p administered holoxan (50 mg/kg b.wt); 4/rats i.p administered N-acetyl-L-cysteine (160 mg/kg b.wt); 5/rats i.p administered holoxan and N-acetyl-L-cysteine at the same doses. After medications, females rats were allowed to mate with males and the pregnant rats were sacrificed on day 18 of gestation. Premating treatment with holoxan showed reduction (p50.05) in reproductive performance. Whereas administration of N-acetyl-L-cysteine prior to treatment with holoxan and then concurrently with it modulated significantly fertility index, progesterone level, decreasing postimplantation loss, resorbed fetuses and improved fetal growth. Additionally, holoxan elevated the renal nicotinamide dinucleotide phosphate (NADPH) oxidase activity, oxidative stress, renal functions and caused histological changes in renal tissue. N-Acetyl-L-cysteine treatment reduced (p50.05) renal tissue NADPH oxidase, nitric oxide, malondialdehyde and improved super oxide dismutase (SOD) depletion, elevated levels phosphate, total protein and calcium as well as prevented renal histological damages. N-Acetyl-L-cysteine can confer protection against nitrosative and oxidative stresses in renal tissue induced by holoxan by suppressing NADPH oxidase activation, malondialdehyde, nitric oxide and restoring SOD activity which led to the reduction of reactive oxygen species production and subsequently might effectively improve the gonadal hormone disturbance and reproductive functions. ARTICLE HISTORY

show abstract

“…Several studies demonstrated that the administration of a GnRH analog decreased primordial follicle loss after chemotherapy in an animal model [15,183,184,185]. A clinical study showed that 281 breast cancer patients who received chemotherapy with a GnRH analog showed significantly attenuated POF [186].…”

Section: Melatonin and Other Adjuvant Agents For Protection Againsmentioning

confidence: 99%

Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy

Jang

Hong

Choi

2017

IJMS

View full text Add to dashboard Cite

Premature ovarian failure is one of the side effects of chemotherapy in pre-menopausal cancer patients. Preservation of fertility has become increasingly important in improving the quality of life of completely recovered cancer patients. Among the possible strategies for preserving fertility such as ovarian tissue cryopreservation, co-treatment with a pharmacological adjuvant is highly effective and poses less of a burden on the human body. Melatonin is generally produced in various tissues and acts as a universally acting antioxidant in cells. Melatonin is now more widely used in various biological processes including treating insomnia and an adjuvant during chemotherapy. In this review, we summarize the information indicating that melatonin may be useful for reducing and preventing premature ovarian failure in chemotherapy-treated female patients. We also mention that many adjuvants other than melatonin are developed and used to inhibit chemotherapy-induced infertility. This information will give us novel insights on the clinical use of melatonin and other agents as fertoprotective adjuvants for female cancer patients.

show abstract

Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice

Abstract: This study has showed a dose-dependent protective effect of GnRH analogue on ovarian reserve against ovarian toxic chemotherapy, thus demonstrating an important role of GnRH analogues in fertility preservation.

Cited by 25 publications

References 31 publications

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application

The effects ofN-acetyl-l-cysteine on the female reproductive performance and nephrotoxicity in rats

Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy

Contact Info

Product

Resources

About